Insider · CIK 0001288859
Robert I Blum
ceopresidentofficerdirector
Files at CYTK (CYTOKINETICS INC). First filing Nov 4, 2024, latest Sep 28, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 11
$0 bought, $13M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CYTK: CYTOKINETICS INC
CYTKOct 9, 2026 · close 62.91
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | CYTOKINETICS INC | $491k 7,500 shares | -3% | +23% from low-24% from high | |
| 40Moderate | CYTOKINETICS INC | $7.3M 105,426 shares | -27% | - | |
| 40Moderate | CYTOKINETICS INC | $611k 15,000 shares | -3% | - | |
| 45Moderate | CYTOKINETICS INC | $1.1M 25,000 shares | -7% | - | |
| 59Moderate | CYTOKINETICS INC | $561k 12,648 shares | -4% | - | |
| 61Notable | CYTOKINETICS INC | $737k 16,970 shares | -4% | - | |
| 55Moderate | CYTOKINETICS INC | $375k 8,743 shares | -2% | - | |
| 45Moderate | CYTOKINETICS INC | $1.1M 25,000 shares | -6% | - | |
| 18Weak | CYTOKINETICS INC | $254k 5,000 shares | -1% | - | |
| 18Weak | CYTOKINETICS INC | $253k 5,000 shares | -1% | - | |
| 18Weak | CYTOKINETICS INC | $258k 5,000 shares | -1% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | CYTK CYTOKINETICS INC | MOption exercise Common Stock10b5-1 | +7,500 | $10.60 | $80k | 286,044 | 13 d ago |
| Sep 28, 2026 | CYTK CYTOKINETICS INC | SOpen-market sale Common Stock10b5-1 | -7,500 | $65.46 | $491k | 278,544 | 13 d ago |
| Sep 28, 2026 | CYTK CYTOKINETICS INC | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 149,245 | 13 d ago |
| Sep 14, 2026 | CYTK CYTOKINETICS INC | MOption exercise Common Stock10b5-1 | +7,500 | $10.60 | $80k | 385,320 | 26 d ago |
| Sep 14, 2026 | CYTK CYTOKINETICS INC | SOpen-market sale Common Stock10b5-1 | -7,500 | $73.44 | $551k | 377,820 | 26 d ago |
| Sep 14, 2026 | CYTK CYTOKINETICS INC | GGift Common Stock10b5-1 | -1,350 | $0.00 | $0 | 376,470 | 26 d ago |
| Sep 14, 2026 | CYTK CYTOKINETICS INC | GGift Common Stock10b5-1 | -97,926 | $0.00 | $0 | 278,544 | 26 d ago |
| Sep 14, 2026 | CYTK CYTOKINETICS INC | GGift Common Stockindirect: by Trust 3. Beneficial Ownership Disclaimed.10b5-1 | +97,926 | $0.00 | $0 | 97,926 | 26 d ago |
| Sep 15, 2026 | CYTK CYTOKINETICS INC | SOpen-market sale Common Stockindirect: by Trust 3. Beneficial Ownership Disclaimed.10b5-1 | -97,926 | $69.33 | $6.8M | 0 | 26 d ago |
| Sep 14, 2026 | CYTK CYTOKINETICS INC | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 156,745 | 26 d ago |
| Mar 31, 2025 | CYTK CYTOKINETICS INC | SOpen-market sale Common Stock10b5-1 | -15,000 | $40.75 | $611k | 427,629 | Mar 31, 2025 |
| Mar 14, 2025 | CYTK CYTOKINETICS INC | AGrant or award Common Stock | +116,096 | $0.00 | $0 | 480,277 | Mar 18, 2025 |
| Mar 14, 2025 | CYTK CYTOKINETICS INC | AGrant or award Incentive Stock Option (Right to Buy)derivative | +2,254 | $0.00 | $0 | 2,254 | Mar 18, 2025 |
| Mar 14, 2025 | CYTK CYTOKINETICS INC | AGrant or award Non-Qualified Stock Option (Right to Buy)derivative | +176,547 | $0.00 | $0 | 176,547 | Mar 18, 2025 |
| Mar 17, 2025 | CYTK CYTOKINETICS INC | SOpen-market sale Common Stock10b5-1 | -25,000 | $44.65 | $1.1M | 339,181 | Mar 17, 2025 |
| Mar 17, 2025 | CYTK CYTOKINETICS INC | SOpen-market sale Common Stock | -12,648 | $44.38 | $561k | 326,533 | Mar 17, 2025 |
| Mar 6, 2025 | CYTK CYTOKINETICS INC | SOpen-market sale Common Stock | -16,970 | $43.44 | $737k | 364,181 | Mar 7, 2025 |
| Mar 5, 2025 | CYTK CYTOKINETICS INC | SOpen-market sale Common Stock10b5-1 | -25,000 | $43.23 | $1.1M | 381,151 | Mar 5, 2025 |
| Mar 3, 2025 | CYTK CYTOKINETICS INC | SOpen-market sale Common Stock | -8,743 | $42.88 | $375k | 406,151 | Mar 5, 2025 |
| Dec 3, 2024 | CYTK CYTOKINETICS INC | AGrant or award Common Stock | +11,529 | $0.00 | $0 | 409,207 | Dec 5, 2024 |
| Dec 3, 2024 | CYTK CYTOKINETICS INC | FTax withholding Common Stock | -5,843 | $51.51 | $301k | 403,364 | Dec 5, 2024 |
| Dec 3, 2024 | CYTK CYTOKINETICS INC | AGrant or award Common Stock | +11,530 | $0.00 | $0 | 414,894 | Dec 5, 2024 |
| Dec 2, 2024 | CYTK CYTOKINETICS INC | MOption exercise Common Stock10b5-1 | +5,000 | $6.67 | $33k | 402,678 | Dec 2, 2024 |
| Dec 2, 2024 | CYTK CYTOKINETICS INC | SOpen-market sale Common Stock10b5-1 | -5,000 | $50.76 | $254k | 397,678 | Dec 2, 2024 |
| Dec 2, 2024 | CYTK CYTOKINETICS INC | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 54,727 | Dec 2, 2024 |
| Nov 18, 2024 | CYTK CYTOKINETICS INC | MOption exercise Common Stock10b5-1 | +5,000 | $6.67 | $33k | 402,456 | Nov 19, 2024 |
| Nov 18, 2024 | CYTK CYTOKINETICS INC | SOpen-market sale Common Stock10b5-1 | -5,000 | $50.55 | $253k | 397,456 | Nov 19, 2024 |
| Nov 18, 2024 | CYTK CYTOKINETICS INC | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 59,727 | Nov 19, 2024 |
| Nov 1, 2024 | CYTK CYTOKINETICS INC | MOption exercise Common Stock10b5-1 | +5,000 | $6.67 | $33k | 402,456 | Nov 4, 2024 |
| Nov 1, 2024 | CYTK CYTOKINETICS INC | SOpen-market sale Common Stock10b5-1 | -5,000 | $51.63 | $258k | 397,456 | Nov 4, 2024 |
| Nov 1, 2024 | CYTK CYTOKINETICS INC | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 64,727 | Nov 4, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.